lipogenesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
On 16 November, Hezbollah conducted eight anti-tank missiles targeting Israeli forces and military infrastructure. In the afternoon, Hezbollah attacked numerous towns near the border and targeted military gatherings in Shtula and Hadab Yaron. The IDF responded heavily in southern Lebanon and Israeli warplanes raided Hezbollah targets. Hezbollah announced that two of its members were killed. Four days later, the IDF base of Biranit suffered heavy damage from a Hezbollah barrage using Burkan rockets. IDF fighter jets struck numerous Hezbollah military targets, and soldiers struck a militant cell near Metula. The historically significant St. George church was heavily damaged in Yaroun after it was shelled by the IDF. The house of Amal Movement MP Kabalan Kabalan was also hit with rocket fire. Hezbollah claimed an attack on the IDF's 91st Division barracks at Baranit. On 21 November, an IDF airstrike in Kafr Kila killed an elderly woman and injured her granddaughter. Another team of journalists were targeted in an IDF strike near Tayr Harfa which killed three people, including two Al Mayadeen journalists, a reporter and a photojournalist, and a guide. On the same day, four members of the Al-Qassam Brigades were killed after an IDF strike on a car near Chaaitiyeh. A Hezbollah member was also killed in a separate attack in Khiam. Hezbollah told Al Jazeera that it would "respect" the temporary ceasefire deal between Israel and Hamas reached on 24 November 2023.
Although an estimated 43,000 species of bacteria have been named, most of them have never been studied. In fact, just 10 bacterial species account for half of all publications, whereas nearly 75% of all named bacteria have no academic research devoted to them. The best-studied species, Escherichia coli, has more than 300,000 studies published on it, but many of these papers likely use it only as a cloning vehicle to study other species, without providing any insight into its own biology. 90% of scientific studies on bacteria focus on less than 1% of species, mostly pathogenic bacteria relevant to human health. While E. coli is probably the best-studied bacterium, a quarter of its 4000 genes are poorly studied or remain uncharacterized. Some bacteria with minimal genomes (< 600 genes, e.g. Mycoplasma) usually have a large fraction of their genes functionally characterized, given that most of them are essential and conserved in many other species.
Different genotypes may compete with each other in a way that is not beneficial for the population. A pure line optimized for a certain environment or usage outperforms the CCP under these specific conditions. There is no reason to believe that the Darwinian selection will work in the desired direction for traits such as baking quality. Natural selection and in-field human selection act on the plant stage, not the seed stage. Common Bunt is a seed borne disease in wheat. In conventional farming it is controlled by fungicide treatment of seeds. In organic farming seeds can be cleaned by brushing before sowing, but it is also desirable that plants have genetic resistance. A CCP, including crosses of resistant cultivars, was grown with heavy common bunt infection for 5 years and it appeared to get more resistant, but the common bunt's virulence appeared to change at least as fast. The overall result was that infection levels went up.
== Promethium-147 == Promethium-147 beta decays to the long-lived primordial radioisotope samarium-147 with a half-life of 2.6234 years, emitting low-energy beta radiation without gamma emission. It is a common fission product, produced in nuclear reactors and in trace quantities in nature, where it is also produced by the alpha decay of europium-151. In the reactor environment, it is almost exclusively produced through beta decay of neodymium-147 as usual for fission products. The isotopes 142-146Nd, 148Nd, and 150Nd are all stable with respect to beta decay, so the isotopes of promethium with those masses are not produced by beta decay and are therefore not significant fission products (as they could only be produced directly, rather than through a beta-decay chain). 149Pm and 151Pm are, but have half-lives of only 53.08 and 28.40 hours, so are not found in spent nuclear fuel that has been cooled for months or years. Promethium-147 is used as a beta particle source and a radioisotope thermoelectric generator (RTG) fuel; its power density is about 2 watts per gram. Mixed with a phosphor, it was used to illuminate the Apollo Lunar Module electrical switch tips and the control panels of the Lunar Roving Vehicle. For luminescent applications, it has generally been replaced by tritium, which is even safer and has a longer half-life (12.32 years).
Sources: en.wikipedia.org
The colony's men and women received 698 decorations during the war; whites received 689 while black troops won nine. No coloured or Indian serviceman was decorated. Army officers won 269 decorations while the other ranks received 158; the air force officers and other ranks respectively won 184 and 72 decorations. All eight decorated Southern Rhodesian naval personnel were officers. Of the seven decorated women, all but one held commissioned rank. Two hundred and fifty-three Southern Rhodesians were mentioned in despatches during the war. MacDonald records 916 Southern Rhodesian fatalities from enemy action during World War II—498 airmen, 407 ground troops, eight seamen and three female personnel—and 483 wounded, of whom 434 were soldiers, 47 were airmen and two were sailors.
=== Explosives === Guncotton CE/TNT Nobel 808 plastic explosive Nobel 851 plastic explosive Nobel 852 plastic explosive PE2 plastic explosive SX2 sheet explosive PE3 plastic explosive PE3A plastic explosive PE4 plastic explosive - Both as individual sticks and as a slab charge (L3A1) No. 1 Mk 3-6 6 Inch Beehive Demolition Charge No. 2 Mk 1 General Wade Arched Demolition Charge No. 3 Mk 1 Hayrick Demolition Charge No. 11 Mk 1 Beehive Demolition Charge No. 14 Mk 1 Hayrick Demolition Charge - Both as individual charges and as part of the L1A1 Necklace Charge kit Bangalore torpedo No. 1 Baby Viper Mine Clearing Line Charge
== Effects == Hydrocodone causes respiratory depression and miosis. Hydrocodone decreases gastrointestinal (GI) motility by increasing smooth muscle tone and decreasing propulsive contractions, which may result in constipation. Hydrocodone causes dilation of peripheral blood vessels, which can cause hypotension and syncope. Vasodilation coupled with histamine release can result in pruritus, sweating and flushing. Hydrocodone, like other opioids, stimulates the secretion of prolactin, growth hormone (GH), insulin and glucagon. Conversely, hydrocodone inhibits adrenocorticotropic hormone (ACTH), cortisol and luteinizing hormone (LH) secretion. Chronic hydrocodone use can lead to androgen deficiency, which may result in low libido, impotence, erectile dysfunction, amenorrhea or infertility. Hydrocodone use can suppress the immune system.
Americium-242m (half-life 141 years) is one of the rare cases, like 108mAg, 166mHo, 180mTa, 186mRe, 192mIr, 210mBi, 212mPo and others, where a higher-energy nuclear isomer is more stable than its ground state. While that ground state, 242Am, decays with half-life 16.02 hours by beta emission or electron capture, in a typical example of spin-forbiddenness the isomer does not decay by those modes, but falls to the ground state very slowly (99.55% of decays) or emits an alpha particle (0.45%, partial half-life 31 ky). 242mAm is fissile with a low critical mass, comparable to that of 239Pu. It has a very high fission cross section, and is quickly destroyed if it is produced in a nuclear reactor. It has been investigated whether this isotope could be used for a novel type of nuclear rocket.
For example, RasGTP signals link with the mitogen activated protein kinase (MAPK) cascade to amplify the allosteric activation of proliferative transcription factors such as Myc and CREB. Earl Wilbur Sutherland Jr., discovered second messengers, for which he won the 1971 Nobel Prize in Physiology or Medicine. Sutherland saw that epinephrine would stimulate the liver to convert glycogen to glucose (sugar) in liver cells, but epinephrine alone would not convert glycogen to glucose. He found that epinephrine had to trigger a second messenger, cyclic AMP, for the liver to convert glycogen to glucose. The mechanisms were worked out in detail by Martin Rodbell and Alfred G. Gilman, who won the 1994 Nobel Prize. Secondary messenger systems can be synthesized and activated by enzymes, for example, the cyclases that synthesize cyclic nucleotides, or by opening of ion channels to allow influx of metal ions, for example Ca2+ signaling. These small molecules bind and activate protein kinases, ion channels, and other proteins, thus continuing the signaling cascade.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.